132682-24-7

Basic information

• Product Name: 2-Oxazolidinone, 4-(iodomethyl)-, (4S)-
• CAS NO: 132682-24-7
• Molecular Formula: C4H6INO2
• Molecular Weight: 227.002
• Mol File: 132682-24-7.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 2-Oxazolidinone, 4-(iodomethyl)-, (4S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Oxazolidinone, 4-(iodomethyl)-, (4S)-(132682-24-7)
• EPA Substance Registry System: 2-Oxazolidinone, 4-(iodomethyl)-, (4S)-(132682-24-7)

Safety Data

• Hazardous Substances Data: 132682-24-7(Hazardous Substances Data)

Upstream product

• 867153-75-1 (S)-4-iodomethyl-3-[(R)-1-phenylethyl]oxazolidine-2-one 
• 154669-49-5 [(S)-2-oxooxazolidin-4-yl]methyl-4-methylbenzenesulfonate 

Downstream Products

• 210635-71-5 (S)-4-[(Methyl-diphenyl-silanyl)-methyl]-oxazolidin-2-one 
• 210635-72-6 (S)-4-[(tert-Butyl-diphenyl-silanyl)-methyl]-oxazolidin-2-one 
• 210635-70-4 (S)-4-[(Dimethyl-phenyl-silanyl)-methyl]-oxazolidin-2-one 
• 210635-69-1 (S)-4-[(Triphenylsilanyl)-methyl]-oxazolidin-2-one 
• 132682-21-4 (S)-(+)-4-(2-oxazolidonyl)-methyltriphenylphosphonyl iodide 
• 154669-73-5 (4R)-4-(2-oxo-2-phenylethyl)-1,3-oxazolidin-2-one 

Relevant articles and documents

Design and synthesis of analogues of the sphingosine-1-phosphate receptor 1 agonist IMMH001 with improved phosphorylation rate in human blood

IMMH001, which is a prodrug for sphingosine-1-phosphate receptor 1 (S1P1) agonist, is converted to the active form, its monophosphate ester (S)-IMMH001-P, by sphingosine kinase 1 (SphK1) and sphingosine kinase 2 (SphK2) in vivo. In this study, we designed head-piece-modified analogues of IMMH001 based on structural information and prepared them with an efficient modular synthetic strategy. The analogues showed higher phosphorylation rates in human blood than the parent compound. These results indicated that the pro-R hydroxymethyl in the head-piece-moiety of IMMH001 prevents the pro-S hydroxymethyl from being phosphorylated by the kinase and ATP. The analogues may have better therapeutic potential.

SPHINGOLIPID DERIVATIVES AND THE COMPOSITION FOR ANTI-CANCER CONTAINING THE SAME

Disclosed are a novel sphingolipid derivative having a sphingosine kinase suppressing activity and a composition containing the same. When the newly synthesized sphingolipid derivative of the invention is used, it is possible to maintain concentrations of ceramide and sphingosine to be high by preventing ceramide and sphingosine from being phosphorylated due to sphingosine kinase since an activity of sphingosine kinase is suppressed. In addition, since the apoptosis is induced in a cancer cell by ceramide and sphingosine, it is possible to treat or prevent a cancer or disease related to the cancer. Further, it is possible to treat or prevent a hyper- proliferative disease such as cancer or proliferation-promoting activity of sphingosine kinase. Accordingly, the composition containing the same can be used as a composition for suppressing sphingosine kinase and a composition for treating or preventing a cancer or hyper-proliferative disease.

Investigations of a nucleophilic alaninol synthon derived from serine

A nucleophilic synthon, (S)-(+)-4-(2-oxazolidonyl)-methyltriphenylphosphinyl iodide 6, available from L-serine in five steps (overall yield of 52%), reacts with aldehydes to produce alkenes in good to excellent yields (74-89%) and, in some cases, provides